© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Latest Conference Articles
Real-World Evidence Reveals Key Insights on Hidradenitis Suppurativa
March 7th 2025
Two posters at AAD 2025 highlighted different challenges of managing patients with HS.
Bimekizumab Demonstrates Sustained Efficacy in Moderate-to-Severe Plaque Psoriasis Over Five Years
March 7th 2025
AAD 2025. New research indicates that dual inhibition of IL-17A and IL-17F with bimekizumab maintains high rates of complete skin clearance for up to 5 years.
Roflumilast Foam 0.3% Significantly Reduces Pruritus and Improves Quality of Life in Scalp and Body Psoriasis
March 7th 2025
More than half (55.4%) of roflumilast-treated patients achieved a score of 0 or 1 vs 19.8% in the vehicle group on the Worst Itch-NRS numeric rating scale.
Roflumilast Cream 0.15% Well Tolerated in Atopic Dermatitis Patients with Prior Treatment Failures
March 7th 2025
Participants in the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials had failed treatment with topical corticosteroids and calcineurin inhibitors or crisaborole.
Tildrakizumab Shows Efficacy for Nail Psoriasis in Phase 3b Trial
March 7th 2025
The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.
AAD 2025: Clear Skin in Half of Patients Who Received Monthly Maintenance Injection of Ebglyss for AD
March 7th 2025
The findings from the long-term extension ADjoin study will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.
AAD 2025: Atopic Dermatitis Preview
March 7th 2025
Preview the posters and abstracts covering atopic dermatitis advances from Arcutis, Incyte, Lilly and Sanofi/Regeneron.
AAD 2025 preview: Dermatologist Mona Shahriari, MD, on Roflumilast and Other Nonsteroidal Topicals for Atopic Dermatitis
March 7th 2025
There are 3 classes of nonsteroidal topical therapies for atopic dermatitis that target the specific underlying pathophysiology of the skin disease. Shahriari provides a primer as physicians prepare for AAD 2025.
Depemokimab Shows Significant Improvements in Rhinosinusitis with Nasal Polyps: New Research
March 5th 2025
AAAAI 2025: Data from the ANCHOR-1 and ANCHOR-2 phase 3 trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing vs placebo.
What to Know Before AAD 2025: Product Snapshots of Nonsteroidal Topical Treatments for Eczema
March 4th 2025
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.